BRIEF-Bionomics Receives FDA Clearance Of IND For Evaluation Of BNC210 In Phase 2 Social Anxiety Disorder Prevail Study
BRIEF-Bionomics Receives FDA Clearance Of IND For Evaluation Of BNC210 In Phase 2 Social Anxiety Disorder Prevail Study
Brief-Bionomics获得FDA批准在第二阶段社交焦虑障碍流行研究中评估BNC210的IND
Nov 1 (Reuters) - Bionomics Ltd BNO.AX :
路透11月1日电-Bionomics Ltd BNO.AX:
* RECEIVES FDA CLEARANCE OF IND FOR EVALUATION OF BNC210 IN A PHASE 2 SOCIAL ANXIETY DISORDER PREVAIL STUDY
*获得FDA批准在社交焦虑症流行研究中评估BNC210的IND
Source text for Eikon: ID:nASX50fDqk Further company coverage: BNO.AX
Eikon的源文本:ID:nASX50fDqk进一步的公司报道:BNO.AX
((Reuters.Briefs@thomsonreuters.com;))
(Reurs.Briefs@thomsonreurs.com;)